Welcome to our dedicated page for Vyome Holdings SEC filings (Ticker: HIND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Vyome Holdings, Inc. (NASDAQ: HIND) filings with the U.S. Securities and Exchange Commission, along with AI-powered tools that help interpret the information. Vyome is a clinical-stage healthcare holding company focused on immuno-inflammatory conditions, AI-driven health applications, and AI-enabled medical devices, and its SEC filings offer structured detail on these activities.
Investors can review current reports on Form 8-K, where Vyome discloses material events such as its streamlined Nasdaq listing, financial results for reporting periods, and transactions like the acquisition of substantially all assets of Oculo, Inc. or the announcement of a binding letter of intent involving LiveChain, Inc. and Humanyze. These filings also confirm that Vyome’s common stock, par value $0.001 per share, is listed on The Nasdaq Capital Market under the symbol HIND and that the company qualifies as an emerging growth company.
The definitive proxy statement on Schedule 14A (DEF 14A) is another key document. It describes matters submitted to stockholders at the annual meeting, including the election of Class I directors, approval of the Vyome Holdings, Inc. 2025 Equity Incentive Plan, ratification of the independent registered public accounting firm, and advisory votes on executive compensation. The proxy statement also outlines governance structures and provides context on how the board oversees Vyome’s strategy.
Through this page, users can quickly locate Vyome’s quarterly and annual reports when available, as well as any future registration statements, proxies, or additional 8-Ks that discuss clinical progress for VT-1953 and other programs, capital structure details, or changes in governance. AI-generated summaries highlight the main points in lengthy documents, helping readers understand how specific items—such as equity plans, material transactions, or board decisions—relate to Vyome’s broader focus on immuno-inflammation, AI initiatives, and the US–India innovation corridor.
Vyome Holdings Form 4: This Form 4 reports that Venkat Nelabhotla, President, CEO and a director, received 7 shares of Vyome Holdings common stock as a result of a merger on 08/15/2025. Under the Merger Agreement, each 5,000 shares of Vyome Therapeutics common stock converted into 1 share of Vyome Holdings common stock. The reporting person exchanged 35,000 Vyome Therapeutics shares and received 7 Vyome Holdings shares. The Form 4 was filed as a single reporting person and is signed on 09/22/2025.
John M. Tincoff III filed an initial Form 3 reporting his relationship to Vyome Holdings, Inc. (ticker shown in the filing as HIND) as a Director. The event date is 08/15/2025. The filing states no securities are beneficially owned by the reporting person. The form is signed and dated 09/18/2025.